Eisai Group will promote creating solutions (new drugs) based on scientific evidence in the areas of its expertise: neurology and oncology. In addition, Eisai is committed to maximizing value for patients by developing additional formulations and expanding indications of our global brands: Halaven®, Lenvima®. In the oncology area, our in-house discovered and developed anticancer agent Halaven has been approved for use in the treatment of breast cancer in over 75 countries and also for use in the treatment of malignant soft tissue sarcoma in over 75 countries. Lenvima, another anticancer agent discovered and developed in-house, has been approved for use in the treatment of thyroid cancer in over 70 countries, including Japan, the United States, in Europe, and in Asia. Additionally, it has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in over 60 countries including the United States and Europe. (In Europe, the brand name for this indication is Kisplyx®.) Lenvima has also been approved for use in the treatment of hepatocellular carcinoma in over 70 countries including in Japan, the United States, China and other countries in Europe and in Asia. Finally, Lenvima has been approved for use in the treatment of endometrial cancer in combination with pembrolizumab in over 10 countries, including the United States, Canada and Australia.